Tag: Mirvetuximab soravtansine
ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...
ImmunoGen Submits Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer
Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...
Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
The Phase 3 SOROYA trial demonstrated promising response rates with mirvetuximab soravtansine, previously known as IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...
Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...
ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...
AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...
Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...
ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...
Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...
Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to...
In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant...
FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity
Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin®; Genentech/Roche)...
ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...
The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...
ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine
Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...
